Literature DB >> 27128719

Emerging trends and risk factors for perianal surgery in Crohn's disease: a 20-year national population-based cohort study.

Vivek Chhaya1, Sonia Saxena, Elizabeth Cecil, Venkataraman Subramanian, Vasa Curcin, Azeem Majeed, Richard C Pollok.   

Abstract

BACKGROUND: Little is known about the rates of perianal surgery (PAS) in Crohn's disease (CD). Our aim was to determine trends in PAS, the timing of surgery relative to the diagnosis of CD and to identify subgroups at risk of PAS.
MATERIALS AND METHODS: We identified 9391 incident cases of CD between 1989 and 2009. We defined three eras: era 1 (1989-1995), era 2 (1996-2002) and era 3 (2003-2009), and determined trends in procedure type and the time to first PAS relative to the date of diagnosis. We used Kaplan-Meier analysis to calculate the rate of first PAS and performed Cox regression to determine subgroups at risk of PAS.
RESULTS: Among the 9391 incident cases of CD, 405 (4.3%) underwent PAS. The overall rate of PAS was 5.5% [95% confidence interval (CI): 4.9-6.2%] 10 years after diagnosis. 34% (n=137) of all patients undergoing PAS had surgery in the 5 years before CD diagnosis. Abscess drainage increased from 34 to 58%, whereas proctectomy decreased from 16 to 6% between eras 1 and 3, respectively. Men [hazard rate (HR) 1.51, 95% CI: 1.24-1.84], those aged 17-40 years (HR 1.69, 95% CI: 1.09-2.02 vs. those aged >40 years) and those with a history of previous intestinal resection (HR 28.5, 95% CI: 22.2-36.5) were more likely to have PAS.
CONCLUSION: Around one-third of patients have a PAS in the 5 years preceding their diagnosis of CD. Surgical practice has changed over 20 years, with a decrease in proctectomy and a concurrent increase in abscess drainage that is likely to reflect improvements in therapeutic practice.

Entities:  

Mesh:

Year:  2016        PMID: 27128719     DOI: 10.1097/MEG.0000000000000651

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

Review 1.  Optimized timing of using infliximab in perianal fistulizing Crohn's disease.

Authors:  Xue-Liang Sun; Shi-Yi Chen; Shan-Shan Tao; Li-Chao Qiao; Hong-Jin Chen; Bo-Lin Yang
Journal:  World J Gastroenterol       Date:  2020-04-14       Impact factor: 5.742

2.  Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study.

Authors:  Ping Zhu; Jin-Fang Sun; Yun-Fei Gu; Hong-Jin Chen; Min-Min Xu; You-Ran Li; Bo-Lin Yang
Journal:  BMC Gastroenterol       Date:  2022-01-10       Impact factor: 3.067

3.  Effect of smoking on the development and outcomes of inflammatory bowel disease in Taiwan: a hospital-based cohort study.

Authors:  Bor-Cheng Chen; Meng-Tzu Weng; Chin-Hao Chang; Ling-Yun Huang; Shu-Chen Wei
Journal:  Sci Rep       Date:  2022-05-10       Impact factor: 4.379

4.  Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn's Disease.

Authors:  Hejun Zhou; Xuehong Wang; Feihong Deng; Pianpian Xia; Zengrong Wu
Journal:  Int J Gen Med       Date:  2021-07-13

5.  Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts.

Authors:  Tom Thomas; Joht Singh Chandan; Venice Sze Wai Li; Cheuk Yin Lai; Whitney Tang; Neeraj Bhala; Gilaad G Kaplan; Siew C Ng; Subrata Ghosh
Journal:  PLoS One       Date:  2019-09-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.